Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: Not simple math

Therapeutic Delivery

Volumn 5, Issue 3, 2014, Pages 297-317

  Ehrick, Jason D ^a   Wylie, Jennifer ^a   Goodey, Adrian P ^a   Li, Ying ^a   Liu, Oscar ^a   Donovan, Brent ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; EXCIPIENT;

ASTHMA; BLISTER PACK; BRONCHOCONSTRICTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG FORMULATION; DRUG MARKETING; DRUG POTENTIATION; DRY POWDER INHALER; FOOD AND DRUG ADMINISTRATION; HUMAN; LONG TERM CARE; LUNG FUNCTION; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; METERED DOSE INHALER; MONOTHERAPY; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; UNITED STATES;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG APPROVAL; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY CONTROL; TECHNOLOGY, PHARMACEUTICAL;

EID: 84896740696     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.4     Document Type: Review

References (155)

1. WHO, Global Surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. www.who.int/gard/publications/GARD%20 Book%202007.pdf
2. Hoyert DL, Xu JQ. Deaths: preliminary data for 2011. Natl Vital Stat. Rep. 61(6), 1-65 (2012) National Center for Health Statistics, Hyattsville, MD, USA
3. WHO top 10 causes of death 2011. www.who.int/mediacentre/factsheets/ fs310/en/index.html
4. Fitzgerald MF, Fox CJ. Emerging trends in the therapy of COPD: bronchodilators as and combination therapies. Drug Disc. Today 12(11/12), 472-478 (2007).
5. Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 19(2), 257-264 (2010).
6. Hanania NA, Cazzola M. Current and future perspectives on optimised treatments for chronic obstructive pulmonary disease. Eur. Respir. Dis. 6, 28-37 (2010).
7. Welte T. Optimizing treatment for COPD-new strategies for combination therapy. Int. J. Clin. Pract. 63 (8), 1163-1149 (2009)
8. Global initiative for chronic obstructive lung disease global strategy for diagnosis, management, and prevention of COPD. www.goldcopd.org/uploads/ users/files/GOLD-Report-2013-Feb20.pdf
9. Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of asthma management: toward understanding how long-acting b-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br. J. Pharmacol. 153, 1090-1104 (2008)
10. American Lung Association trends in asthma morbidity and mortality. www.lung.org/finding-cures/our-research/trend-reports/asthma-trend-report.pdf
11. National Heart, Lung, and Blood Institute asthma care quick reference: diagnosing and managing asthma. guidelines from the national asthma education and prevention program, Expert Panel Report 3. www.nhlbi.nih.gov/guidelines/ asthma/asthg-dln.pdf
12. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344, 219-224 (1994).
13. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur. Respir. J. 19, 182-191 (2002).
14. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunol. 112 (1), 29-36 (2003).
15. Newton R, Leigh R, Giembycz MA. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol. Ther. 125, 286-327 (2010).
16. Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir J. 18, 262-268 (2001).
17. Angus R, Reagon R, Cheesbrough A. Short-acting b2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting b2-agonist or salmeterol/fluticasone propionate combination. Int. J. Clin. Pract. 59(2), 156-162 (2005).
18. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir. Med. 103, 41-49 (2009).
19. Barnes PJ, Nicolini G, Bizzi A, Spinola M, Singh D. Do inhaled corticosteroid/long-acting ba2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc. 33(2), 140-144 (2012).
20. Neugaard BI, Priest JL, Burch SP, Cantrell CR, Foulis PR. Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization. Popul. Health Manag. 14(2), 99-106 (2011).
21. Hesselink AE, Van Der Windt DAWM, Penninx WJH et al. What predicts change in pulmonary function and quality of life in asthma or COPD? J. Asthma 43, 513-519 (2006).
22. Stoloff S W, Stempel DA, Meyer J et al. Improved refill persistence with fluticasone dipropionate and salmeterol in a single inhaler compared with other controller therapies. J. Allergy Clin. Immunol. 113, 245-251, (2004).
23. Nelson HS. Combination therapy of long-acting b agonists and inhaled corticosteroids in the management of chronic asthma. Curr. Allergy Asthma Rep. 5, 123-129 (2005).
24. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting b-agonists in the treatment of asthma. N. Engl. J. Med. 362 (13), 1169-1171 (2010)
25. Value through innovation. www.boehringeringelheim.com/products/ prescription-medicines/chronic-obstructive-pulmonarydisease.html
26. Giraud V. Allaert FA. Improved asthma control with breath-actuated pressurized metered dose inhaler (pMDI): the SYSTER survey. Eur. Rev. Med. Pharmacol. Sci. 13, 323-330 (2009)
27. My symbicort. www.mysymbicort.com/default.aspx
28. Chiesi annual report www.chiesigroup.com/web/guest/chi-siamo/key-figures/ report-finanziari
29. Triohale inhaler. http://star-pharma.com/index.php/cipla/87-inhalers/169- triohale-inhaler
30. ® for asthma and Advair Diskus. www.advair.com
31. ®. http://public.gsk.co.uk/ products/seretide.html
32. What is Dulera? http://dulera.com/mometasone-formoterol/dulera/consumer/ what-is-dulera.jsp
33. Merck Zenhale. www.merck.ca/assets/en/pdf/products/ci/Zenhale-CI-E.pdf
34. Ranbaxy launches Avessa for the treatment of asthma. www.ranbaxy.com/ ranbaxy-launches-avessa-for-the-treatment-of-asthma
35. SkyePharma pipeline products: flutiform. www.skyepharma.com/Products/ Approved- Products/Inhalation-Products/flutiform/De-fault.aspx?id=72
36. GSK prescription medicines. www.gsk.com/products/our-prescription-medi- cines.html
37. Novartis Breezhaler achieves approval for COPD in Europe and Japan. www.novartis.com/newsroom/media-releases/en/2013/1730580.shtml
38. Elpen's Rolenium www.elpen.gr/default.aspx?lang=&pageID=22
39. Taki M, Esmaeili F, Martin GP. The scientific basis and challenges of combined inhaled products. J. Drug. Del. Sci. Tech. 21 (4), 239-300 (2011)
40. Amirall product development pipeline. www.almirall.com/webcorp2/cda/ImD- 03-02.jsp?langSuscripcion=3
41. Amirall Sofotec. www.almirallsofotec.com/en/index.html
42. Almirall strengthens its respiratory fran-chisewith a new generation of Chronic Obstructive Pulmonary Disease treatment. www.almirall.com/webcorp2/cda/ comuni-cacion-detalle-noticia.jsp?id=1483
43. AstraZeneca development pipeline as of 30 June 2013. www.astrazeneca.com/ cs/Satellite?blobcol=u-rldata&blobheader=application%2Fpdf&blo bheadername1=Content-Disposition&blobheadername2=MDT-Type &blobheadervalue1=inline%3B+filename% 3DPipeline-table. pdf&blobheadervalue2=ab inary%3B+charset%3DUTF-8&blobkey=id &blobtable=MungoBlobs&blobwhere=1285657147652&ssbinary=true
44. Pearl Therapeutics Pipeline overview. www.pearltherapeutics.com/pipeline- over-view Pearl pipeline and platform for PT003. www.pearltherapeutics.com/PT003
45. Pearl pipeline and platform for PT010. www.pearltherapeutics.com/PT010
46. Boehringer Ingelheim's once-daily broncho-dilator olodaterol successfully completes Phase II clinical trial program in COPD. www.boehringer-ingelheim. com/news/news-releases/press-releases/2012/21- may-2012-copd.html
47. Chiesi triple product clinical trial. http://clinicaltrials.gov/ct2/show/ NCT01911364?term=respiratory+triple+chiesi&ra nk=1. Accessed Dec 02, 2013
48. Our product pipeline, research and development, GlaxoSmithKline. www.gsk.com/research/our-product-pipe-line.html?hidden=%2Fcontent%2Fgsk%2Fe n%2Fresearch%2Four-product-pipeline&se archType=filter&searchType1= filter&n=%2 Fcontent%2Fgsk%2Fproductspipeline%2Fr espiratory&m= showAll&searchType1=filter &tid=PATH&searchType=filter
49. Quick Search for GSK573719/vilanterol. www.gsk-clinicalstudyregister.com/ quick-search-list.jsp?tab=protocols&phase=All&st udyType= All&population=All&marketing= No&status=All&country= All&item=G SK573719/vilanterol&letterrange=G-K&type=compound
50. GlaxoSmithKline completes transaction to increase its ownership in Theravance. http://investor.theravance.com/releasedetail. cfm?releaseid=674071
51. GSK 2012 annual report. www.gsk.com/content/dam/gsk/globa ls/documents/pdf/GSK-Annual-Report-2012-investor-information.pdf
52. GlaxoSmithKline pharmacokinetic study http://clinicaltrials.gov/ct2/show/ NCT01894386?term=respiratory+GSK&rank=127
53. Novartis clinical pipeline. www.novartis.com/innovation/research-de- velopment/clinical-pipeline/index.shtml
54. Novartis QVA149 Phase III COPD studies meet primary endpoints. www.novartis.com/newsroom/media-releases/en/2012/1599186.shtml
55. Novartis current alliances. www.novartis.com/downloads/about-novar-tis/ current-alliances.pdf
56. Roller CM, Zhang G, Troedson RG, Leach CL, Le Souef PN, Devadason SG. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur. Respir. J. 29(2), 299-306 (2007).
57. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and the dry powder inhaler. Respir. Care. 50 (10), 1313-1322 (2005).
58. Dolovitch MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest 127(1), 335-371 (2005).
59. De Koning JP, Van der Mark TW, Coenegracht PMJ, Tromp TFJ, Frijlink HW. Effect of an external resistance to airflow on the inspiratory flow curve. Int. J. Pharm. 234, 257-266 (2002).
60. Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J. Aerosol Med. 14(3), 281-287 (2001).
61. De Boer AH, Bolhuis GK, Gjaltema D, Haedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler. Int. J. Pharm. 153, 66-77 (1997).
62. Janssens W, Van Den Brande P, Hardeman E et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur. Respir. J. 1, 78-83 (2008).
63. MedaPharma GMBH and Co.: WO2007071313 (2007).
64. AstraZeneca AB: WO2009142588 (2009).
65. Turner DL, Ferrari N, Ford WR et al. TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs. Eur. J. Pharmocol. 641, 213-219 (2010).
66. Turner DL, Ferrari N, Ford WR et al. Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol. Br. J. Pharmacol. 167(3), 515-526 (2012).
67. Nicox S: WO2009037584 (2009).
68. Makovec F: US0253664 (2009).
69. Ngkelo A, Adcock IM. New treatments for COPD. Curr. Opin. Pharmacol. 13, 362-369 (2013).
70. Salama RO, Young PM, Traini D. Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbualine. Drug Deliv. Transl. Res. doi:10.1007/s13346-013-0137-z (2013) (Epub ahead of print).
71. Philip G, Pedinoff A, Vandormael K et al. A Phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma. J. Asthma 47, 1078-1084 (2010).
72. Philip G, Villaran C, Shah S, Vandormael K, Smugar SS, Reiss TF. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. J. Asthma 48, 495-502 (2011).
73. Merck Frosst Canada, Ltd: WO2009052624 (2009).
74. E-Therapeutics Plc: WO2009044141 (2009).
75. Salama RO, Young PM, Rogueda P, Lallement A, Iliev I, Traini D. Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Expert Opin. Pharmocother. 12 (12), 1313-1932 (2011)
76. Protocol Summary for 200587. www.gskclinicalstudyregister.com/protocol- detail.jsp?protocolId=200587&studyId=BB4 C5FD1-A913-46A5-A045-CABEA91AFC16 &compound=Chronic+Obstructive+Pulmon ary+disease&type= Medical+Condition&lett errange=A-F
77. Wielders PL, Ludwig-Sengpiel A, Locantore N, Chan R, Riley JH. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur. Respir. J. 42(4), 972-981 (2013).
78. Cormier YF, Beaulieu MJ, Assayag EI. Relaxant effects of ASM-024, a new compound with dual nicotinic and muscarinic activity, on b-2 agonist desensitized guinea-pig tracheas. Presented at: The American Thoracic Society Conference. Philadelphia, PA, USA, 20 May 2013.
79. Boulet LP, Gauvreau GM, Cockcroft D et al. Effects of ASM-024, a new compound with dual nicotinic and muscarinic activity, on airway responsiveness and allergen-induced responses in mild asthmatics. Presented at: The American Thoracic Society Conference. Philadelphia, PA, USA, 20 May 2013
80. FDA drug safety communication: new safety requirements for long-acting inhaled asthma medications called long-acting b-agonists. www.fda.gov/Drugs/ DrugSafety/Postmarket-DrugSafetyInformationforPatientsandProvid-ers/ucm200776. htm#-Ref252304498
81. Decision resources communication: novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022. http://decisionresources.com/News-and-Events/Press-Releases/Chronic-Obstructive- pulmonary-disease-082813
82. Novartis receives US FDA approval for Ar-capta™ Neohaler™, a novel once-daily bron-chodilator for chronic obstructive pulmonary disease. www.novartis.com/newsroom/media-releases/en/2011/1528013.shtml
83. Guideline on the requirements for clinical documentation for orally inhaled products including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease in adults and for use in the treatment of asthma in children and adolescents. www.ema.europa.eu/docs/en-GB/docu-ment- library/Scientific-guideline/2009/09/WC500003504.pdf
84. Fuglsang A. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD. J. Aerosol Med. Pulm. Drug Deliv. 25(4), 243-247 (2012)
85. FDA draft guidance on fluticasone propionate; salmeterol xinafoate. www.fda.gov/downloads/drug s/guida nce-complianceregulatoryinformation/ guidances/ucm367643.pdf
86. Kotak institutional equities india daily 28 March 2012. www.kotaksecurities.com/pdf/indiadaily/indiadaily28032012.pdf
87. Sweden approves copy of top GSK lung drug. http://uk.reuters.com/article/ 2011/06/06/uk-glaxosmithkline-elpen-idUK-TRE75522E20110606
88. Rossios C, To Y, To M et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur. J. Pharmacol. 670 (1), 244-251(2011).
89. Leach C, Colice G, Luskin A. Particle size of inhaled corticosteroids: Does it matter? J. Allergy Clinical Immunol. 124 (6), S88-S93(2009).
90. ®and Symbicort Turbuhaler following inhalation by severe asthmatics. Inter. J. Pharm. 316, 131-137 (2006)
91. ®; RDD Europe 2011 Poster. http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd= 1306875828000&locale=en-WW&assetType=MMM-Image&assetId= 1273684150281&blobAttribute=ImageFile
92. Sahib MN, Darwis Y, Khiang PK, Tan YTF. Aerodynamic characterization of marketed inhaler dosage forms: high performance liquid chromatography assay method for the determination of budesonide. Afr. J. Pharm. Pharmacol. 4(12), 878-884 (2010).
93. Krummen M, Singh D, Fiebich K, Haeberlin B. Flow-dependent performance of several formoterol dry powder inhalers (DPIs). Eur. Respir. Soc. Abstract 2538 (2006).
94. De Backer W, Devolder A, Poli G, Acerbi D, Monno R, Herpich C, Sommerer K, Meyer T, Mariotti F. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol Med. Pulm. Drug Deliv. 23, 137-148 (2010).
95. Berger R, Berger WE. Particle size and small airway effects of mometasonefuroate delivered by dry powder inhaler. Allergy Asthma Proc. 34, 52-58 (2013).
96. Franchini MK. Particle Engineering. Encyclopedia of Pharmaceutical Technology, 3rd Edition. Swarbrick J, Boylan JC (Eds). CRC Press, Boca Raton, FL, USA (2006).
97. Kaerger JS, Price R. Processing of spherical crystalline particles via a novel solution atomisation and crystallisation by sonication (SAXS) technique. Pharm. Res. 21(2), 372-381 (2004).
98. Matson DW, Fulton JL, Petersen RC, Smith RD. Expansion of supercritical fluid solution: solute formation of powders. Thin films and fibers. Ind. Eng. Chem. Res. 26, 2298-2306 (1987).
99. Clark AR, York P. SCF-Pulmonary pharmaceuticals: the uncoated truth. Respir. Drug Deliv. 1, 317-326 (2006).
100. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, De Simone JM. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127(28), 10096-10100 (2005).
101. Woo WY, Tan RBH, Braatz RD. Precise tailoring of the crystal size distribution by controlled growth and continuous seeding from impinging jet crystallizers. CrystEngComm 13, 2006-2014 (2011).
102. Zeng XM, Martin GP, Marriott C. Chapter 2: Interparticulate Forces in Pharmaceutical Powders, Particulate Interactions in Dry Power Formulations for Inhalation. Informa Healthcare, Zug, Switzerland (2001).
103. Dwivedi S: US12/790710 (2012).
104. Geller DE, Weers J, Heuerding S. Development of an Inhaled dry-powder formulation of tobramycin using PulmoSphere™ Technology. J. Aerosol Med. Pulm. Drug Deliv. 24(4), 175-182 (2011).
105. Cocconi D: EP-2010/001089 (2010).
106. Boehringer Ingelheim. New data show significant improvements in lung function using combination of tiotropium and olodaterolin COPD patients. www.boehringer-ingelheim.com/news/news- releases/press-releases/2012/03- september-2012-copd.html
107. Augustyn S: US8161968 B2 (2004).
108. Galluppi M: US20130000639 A1 (2013)
109. Vectura Corporate site
110. Ziegler D: US8479730 B2 (2005)
111. ® technology-dry powder delivery platform. www.mannkindcorp.com/our-technology-dry-powder-delivery- platform.htm
112. FDA draft guidance for industry. Metered dose inhaler and dry powder inhaler drug products. www.fda.gov/downloads/Drugs/Guidances/ucm070573.pdf
113. Rogueda PGA, Price R, Smith T, Young PM, Traini D. Particle synergy and aerosol performance in non-aqueous liquid of two combination metered dose inhalation formulations: an AFM and Raman investigation. J. Colloid Interface Sci. 361, 649-655 (2011).
114. Parikh, D, Karki S, Hipkiss D. Engineered combination respiratory medicines for localized lung delivery. Presented at: Respiratory Drug Delivery. Phoenix, AZ, USA, 13-17 May 2012.
115. Pennington J, Lena J, Medendorp J, Ewing G. A uHPLC-MS mathematical modeling approach to dry powder inhaler single agglomerate analysis. Drug Dev. Ind. Pharm. 36, 1-9 (2011).
116. Menzeleev R, Derrien Y, Bovet J, Hickey AJ. Unit dose level particle size distribution characterization of combination drug inhalation product. Respir. Drug Deliv. 2, 585-588 (2006).
117. FDA 21 CRF 300.50. Fixed-combination prescription drugs for humans. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=300.50
118. European Medicines Agency guideline on fixed combination medicinal products. www.ema.europa.eu/docs/en-GB/docu-ment-library/Scientific-guideline/ 2009/09/WC500003689.pdf
119. FDA draft guidance for industry for co-development of two or more unmarketed investiga-tional drugs for use in combination. www.fda.gov/downloads/ Drugs/Guidance-ComplianceRegulatoryInformation/Guid-ances/UCM236669.pdf
120. FDA orders safety studies for some asthma drugs. www.reuters.com/article/ 2011/04/15/us-fda-asthma-idUSTRE73E65A20110415
121. FDA drug safety communication: FDA requires post-market safety trials for LABAs. www.fda.gov/Drugs/Drugsafety/ucm251512. htm
122. Adams WP, Ahrens RC, Chen ML et al. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J. Aerosol Med. Pulm. Drug Deliv. 23 (1), 1-29 (2010).
123. O'Conner D, Adams WP, Chen ML et al. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: Workshop summary report. J. Aerosol Med. Pulm. Drug Deliv. 24 (3), 119-135 (2011)
124. WHO report on chronic respiratory diseases. www.who.int/gard/ publications/chronic-re-spiratory-diseases.pdf
125. Monteith D. Developing pharmaceutical products for the complex needs of emerging markets. Presented at: NJPhAST meeting. Hanover, NJ, USA, 21 February 2013.
126. Bhome A. Obstructive airway diseases in India: an insight. Presented at: Inhalation Asia 2013. Hong Kong, 26-28 June 2013
127. Asthma in India. http://decisionresources.com/Products-and-Services/ Report?r=emerim0110
128. Seroflo™ Rotahaler by Cipla. www.mims.com/india
129. Market and product forecasts: asthma in China. www.datamonitor.com/store/ Product/market- and-product-forecasts-asthma-in-china- market-set-to-fragment- as-novel-therapies- launch?productid=HC00219-006
130. Shen A. The Chinese market for asthma and COPD inhalation products. Presented at: Inhalation Asia 2013. Hong Kong, 26-28 June 2013.
131. Yin H. Experience with registration of an inhalation drug product in China. Presented at: Inhalation Asia 2013. Hong Kong, 26-28 June 2013.
132. Filho PPL, Anitunes A, Bomtempo JV. The pharmaceutical industry in Brazil. Chimicaoggi/Chem. Today 30(5) (2012).
133. To T, Stanojevic S, Moores G et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. www.biomedcentral.com/ 1471-2458/12/204
134. Brazil Anvisa searchable database of registered health products available. http://portal.anvisa.gov.br/wps/content/Anvisa+Portal/Anvisa/ Profissional+de+Saude/Assunto+de+Interesse/Precos+de+Medicamentos
135. Brazil's pharmaceutical industry, opportunities for Swiss suppliers. www.switzerland-ge.com/en/blog/brazil%E2%80%99s-pharmaceutical-industry- opportunities-swiss-suppliers
136. Lotvall J. Combination therapy in asthma-fixed or variable dosing in different patients? Curr. Med. Res. Opin. 20 (11) 1711-1727 (2004).
137. Aalbers R. Single inhaler as maintenance and reliever therapy-is it SMART? Lancet 1, 2-3 (2013).
138. Papi A, Corradi M, Pigeon-Francisco C. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomized controlled trial. Lancet 1, 23-31 (2013).
139. Patel M, Pilcher J, Prutchard, A. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomized controlled trial. Lancet 1, 32-42 (2013).
140. Grover C, Armour C, Van Asperen PP, Moles R, Saini B. Medication use in children with asthma: not a child size problem. J. Asthma 48, 1085-1103 (2011).
141. Bush A. Clinical trials research in pediatrics: strategies for effective collaboration between investigator sires and the pharmaceutical industry. Pediatr. Drugs 8(5), 271-277 (2006).
142. Ragupathy R, Tordoff J, Norris P, Reith D. Access to children's medicines in the United Kingdom, Australia and New Zealand in 2002 and 2007. Pharm. World Sci. 32, 386-393 (2010) (1998).
143. Patel M, Shirtcliffe P, Beasley R. The b-2 agonist debate: is there still a problem? Curr. Opin. Allergy Clin. Immunol. 12(00), 1-5 (2012).
144. Jacobs TS, Jones BL, MacGinnitie, AJ. Long-acting beta-agonists and the risk of intensive care unit admission in children. J. Asthma 49(5), 450-455 (2012).
145. McQuaid EL, Kopel SH, Klein RB, Fritz GK. Medication adherence in pediatric asthma: reasoning responsibility, and behavior. J. Pediatr. Psychol. 28(5), 323-333 (2003).
146. Kamps AWA, Van Ewijk B, Roorda RJ, Brand PLP. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr. Pulmonol. 29, 39-42 (2000).
147. Dhand R. Intelligent nebulizers in the age of the internet: the i-neb adaptive aerosol delivery (A AD) system. J. Aerosol Med. Pulm. Drug Deliv. 23(Suppl. 1), iii-v (2010)
148. ® Electronic respiratory medication adherence monitoring solution. www.smartinhaler.com/news/nexus6-receives-510k-clearance-for-smarttrack
149. Trueman P, Taylor D, Lowson K et al. Evaluation of the Scale, Causes and Costs of Waste Medicines. York Health Economics Consortium/School of Pharmacy; University of London, York/London, UK (2010).
150. Pritchard J, Nikander K. Impact of intervention and feedback on adherence to treatment. Respir. Drug Deliv. 1, 271-282 (2012).
151. Wachtel H, Meisenheimer M, Kamin W. Studying compliance: electronic monitoring of respimat soft mist inhaler use in children. Respir. Drug Deliv. 1, 227-238 (2012)
152. Making science happen; novartis strategy and innovation forum. www.novartis.com/downloads/investors/presentations-events/pipeline-update/2010/ 2010-2011-2017-making-science-happen.pdf
153. Sensing City: transforming christchurch into the world's smartest city www.idealog.co.nz/blog/2013/07/sensing-city-transforming-christchurch-worlds- smartest-city
154. Van Sickle D, Maenner MJ, Barrett MA, Marcus JE. Monitoring and improving compliance and asthma control: mapping inhaler use for feedback to patients, physicians and payers. RDD Europe 20131, 119-130 (2013)
155. Describes a new asthma monitoring system, Asthmapolis, which tracks patient reported outcomes and medication use in order to allow patients and physicians to better treat the disease.